Codex DNA, Inc. (DNAY): history, ownership, mission, how it works & makes money

From its origins as Synthetic Genomics Solutions in 2011 to its rebrands-SGI-DNA in 2013, Codex DNA in 2020 and most recently Telesis Bio in 2022-this San Diego-based innovator at 10431 Wateridge Circle has built a focused synthetic biology business led by CEO Todd Nelson, Ph.D. and CTO Dan Gibson, Ph.D., operating publicly on NASDAQ as DNAY and employing a global team that included 209 full-time U.S. staff, 20 part-time U.S. staff and 14 international employees as of December 31, 2022; Telesis Bio's mission to accelerate biomedical discovery is backed by the automated BioXp™ workstation that compresses DNA and mRNA production from weeks to days using Gibson Assembly® and SOLA enzymatic synthesis, supported by a >20,000 sq ft San Diego facility with roughly $10 million in modern equipment and an R&D spend of about $12 million annually; the company reports partnerships with over 100 international research institutions and named collaborations such as the Pfizer deal in January 2022, has seen a 15% increase in customer engagement in 2024 alongside a 30% reduction in carbon footprint and 100% internal audit compliance, and monetizes its platform by selling BioXp™ systems, kits and reagents, offering custom DNA synthesis, licensing proprietary technologies and strategic partnerships-yet despite these commercial levers Telesis Bio reported approximately $19.57 million in trailing-twelve-month revenue as of Q2 2024, representing a decline of -29.68% year-over-year, setting the stage for a closer look at how its technology, partnerships and market positioning stack up against competitors like Thermo Fisher and Twist Bioscience

Codex DNA, Inc. (DNAY) - Intro

• Founded: March 24, 2011 as Synthetic Genomics Solutions, Inc. (wholly owned subsidiary of Synthetic Genomics, Inc.).
• Rebranded to SGI‑DNA, Inc.: February 26, 2013.
• Renamed Codex DNA, Inc.: March 2020, to align with synthetic biology mission.
• Further rebranded to Telesis Bio Inc.: November 7, 2022, signaling expansion into multi‑omic/synthetic biology applications.
• Headquarters: 10431 Wateridge Circle, Suite 150, San Diego, California.

• Public identity and ticker: Historically associated with the DNAY identifier during the Codex DNA era prior to operating under the Telesis Bio name.
• Core mission (historical and transitional): accelerate research and development in synthetic biology by reducing cost, time and error in DNA synthesis and enabling downstream biological design and multi‑omic analyses.

• Automated DNA synthesis platforms: bench‑scale instruments that assemble gene‑length DNA from oligonucleotide building blocks using proprietary assembly chemistries and software automation.
• Reagents and consumables: proprietary enzymatic mixes, templates and assembly reagents sold as recurring consumables for instruments and services.
• Design and software: sequence design, error checking and workflow automation software to optimize constructs and streamline build‑test cycles.
• Custom DNA and gene services: on‑demand synthesis, cloning, and sample delivery for academic and commercial customers.

• Installed base of instruments - drives consumables revenue and service contracts.
• Consumables attach rate - average consumables spend per instrument per year.
• Average order value for custom synthesis - influences service segment revenue.
• R&D spend as % of revenue - indicates reinvestment into platform and capability expansion.
• Employee counts and headcount growth - tied to commercialization and scale (209 FTE U.S., 20 part‑time U.S., 14 FTE international as of 12/31/2022).

• Origins: Initially a wholly owned subsidiary of Synthetic Genomics, Inc., providing a clear early‑stage corporate parent and technology transfer pathway.
• Transitioned through private financing and strategic partnerships prior to public company activity associated with the Codex DNA/Telesis Bio identities.
• Post‑rebrand ownership and public equity structure shifted with corporate transactions and any subsequent financings; investors typically include founders, institutional venture investors and public shareholders when listed.

• Market drivers: demand for rapid DNA constructs, CRISPR workflows, biologic R&D, cell and gene therapy development and synthetic biology research tools.
• Competitive landscape: other DNA synthesis providers, instrument makers, and contract synthesis organizations; success depends on speed, accuracy, price per base and consumables margins.
• Regulatory and IP environment: biotechnology export controls, sequence screening policies and patent portfolios affect product deployment and commercial partnerships.

Codex DNA, Inc. (DNAY): History

• Founded to commercialize automated DNA assembly and synthetic biology workflow tools.
• Transitioned from tool-focused sales to integrated platform and service offerings to increase recurring revenue.
• Public listing enabled access to capital for instrument manufacturing scale-up and R&D expansion.

• Codex DNA, Inc. (DNAY) is publicly traded on NASDAQ under the ticker DNAY.
• The shareholder base is diverse, including institutional investors, individual shareholders, and company insiders.
• Specific ownership percentages for many large holders are not fully disclosed in public summaries; filings provide partial snapshots (e.g., top institutional holders and insider filings).
• The Board of Directors comprises experienced leaders across biotech, diagnostics, and commercialization, providing strategic oversight.
• Executive leadership includes CEO Todd Nelson, Ph.D., and CTO Dan Gibson, Ph.D., both with extensive biotechnology and molecular engineering backgrounds.
• Management maintains active investor communications including SEC filings, earnings releases, and investor presentations to ensure transparency.

• Regular SEC filings (10-Q, 10-K, 8-K) document financials, share counts, and material events.
• Quarterly earnings calls and investor presentations review operational metrics, product adoption, and revenue composition.
• Board committees (audit, compensation, governance) align oversight with shareholder interests and compliance requirements.

Codex DNA, Inc. (DNAY): Ownership Structure

• Mission and values: Codex DNA's mission is to empower scientists by providing innovative synthetic biology solutions that accelerate the discovery and production of novel biomedical products.
• Core values: innovation, integrity, collaboration, customer-centricity, and excellence.
• Operational highlights: in 2024 Codex DNA reported a 15% increase in customer engagement due to improved accessibility; it has partnerships with more than 100 international research institutions; achieved a 30% reduction in carbon footprint year-over-year; and recorded 100% compliance in 2023 internal audits.

• Ticker and listing: DNAY - traded publicly (OTC market).
• Shareholder composition (approximate snapshot): institutional investors, retail holders, and insiders all contribute to ownership dynamics below.

• Product sales: synthetic DNA, automation instruments, and consumables sold to research and biomanufacturing customers.
• Service contracts: custom synthesis, design services, and workflow integration for academic and industry partners.
• Partnerships and licensing: collaborative R&D and IP licensing with >100 international institutions.
• Support and subscription models: software, data services, and recurring reagent supply agreements.

Codex DNA, Inc. (DNAY): Mission and Values

• Core platform: BioXp™ automated workstation - end-to-end synthesis and assembly of DNA and mRNA.
• Proprietary technologies: Gibson Assembly® for seamless fragment assembly; SOLA enzymatic DNA synthesis for rapid, scalable oligonucleotide production.
• Throughput and speed: reduces typical gene synthesis timelines from weeks to days, enabling faster iteration in R&D and product development.

• Annual R&D investment: approximately $12 million focused on improving synthesis fidelity, throughput and application breadth.
• Human capital: workforce of over 80 scientists and engineers with planned expansion of ~25% in the next year to bolster R&D capabilities.
• Facility footprint and assets: single San Diego site >20,000 sq ft; laboratory equipment valued at ~ $10 million.

• Collaborations: active partnerships with academic institutions and biotech companies to integrate cutting-edge research and co-develop workflows and assay-validated constructs.
• Revenue drivers: sales and service of BioXp™ workstations, consumables (enzymes, reagents, cartridges), design and workflow software, and fee-for-service synthesis work for industry and academia.

Codex DNA, Inc. (DNAY): How It Works

• Automated DNA synthesis instruments (e.g., BioXp™ systems) perform high-throughput, bench-top assembly of genes, gene fragments and libraries from designed sequences.
• Consumables-kits, reagents and cartridge systems-support recurring revenue tied to instrument-installed workflows and customer throughput.
• Custom synthesis services provide end-to-end design, build and delivery of DNA constructs for academic, government and commercial customers with variable turnaround times and pricing tiers.
• Proprietary software and automated workflows integrate sequence design, error-checking and production scheduling, reducing manual labor and accelerating R&D timelines.
• Licensing of platform technologies and IP to partners expands usage into therapeutic and industrial applications while generating royalty and license-fee income.

• Instrument sales-one-time revenue from selling automated DNA assembly systems to universities, CROs and biotech companies.
• Consumables and reagents-recurring revenue from kits, cartridges and reagents required per run on installed instruments.
• Custom DNA synthesis services-fee-for-service revenue for project-based or recurring contracts designing and producing DNA constructs.
• License and collaboration income-upfront and milestone payments, plus potential royalties from licensing the company's technology to other firms.
• Strategic partnerships-co-development agreements that include cost-sharing, milestone payments and joint commercialization (e.g., a partnership announced with Pfizer in January 2022 to co-develop synthetic DNA products).

• Vaccine development-rapid design and synthesis of antigen sequences and variants for preclinical testing.
• Gene therapy-production of DNA templates and constructs used in vector design and manufacturing workflows.
• Precision medicine and research-gene libraries, mutational scans and variant testing for academic and commercial discovery programs.
• Industrial biotech and synthetic biology-enzymes, pathways and optimized genes for bioprocessing and production strains.

• Drive instrument adoption to create a recurring consumables revenue base tied to installed systems.
• Offer tiered service levels for custom synthesis to capture both one-off projects and long-term CRO-style contracts.
• Leverage collaborations and licensing (including high-profile partners) to validate technology and generate non-product revenue.
• Target fast-growing use cases-vaccine R&D, gene therapy and precision medicine-to align product roadmaps with high-value customers.

Codex DNA, Inc. (DNAY): How It Makes Money

• Product sales: BioXp™ instruments (one-time equipment revenue plus extended service agreements).
• Consumables & reagents: cartridge-based disposables and chemistry kits for each run; high-frequency, recurring revenue.
• Service revenue: on-demand gene synthesis, library construction, and contract research projects for pharma, biotech, and academic customers.
• Software & support: instrument software licensing, data analysis tools, and maintenance agreements.

• Codex DNA holds a strong position in the synthetic biology market with the BioXp™ system as a leading automated DNA synthesis platform, focused on benchtop automation that shortens timelines from design to construct.
• Key competitors include Thermo Fisher Scientific and Twist Bioscience, both of which offer advanced gene synthesis services and large-scale manufacturing capabilities.
• To maintain competitive edge, Codex DNA is expanding product offerings and enhancing BioXp™ throughput, error correction, and integration with design software and LIMS systems.
• New market initiatives target industrial biotechnology applications (enzyme and pathway prototyping) and personalized medicine (rapid, small-batch constructs), diversifying revenue streams beyond research institutions.
• Sustainability: the company implemented eco-friendly manufacturing processes and targeted a 30% reduction in carbon footprint in 2024 as part of operational improvements and supply-chain optimization.
• Profitability path: management aims to reach profitability by scaling consumables attach-rates, optimizing manufacturing costs, and leveraging strategic partnerships with larger life-science distributors and pharma collaborators.